Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Wayne State team receives $330,000 NSF grant to develop 3-D neural probe for tinnitus

A team of Wayne State University researchers was awarded $330,000 from the National Science Foundation (NSF) to develop a 3-D neural probe. Their aim is to develop an implantable device that will suppress tinnitus, a neurological disorder that affects more than 250 million people worldwide.

21 Jun 2011

University of Texas professor recommends three postulates to find probable cause of AD

After more than 100 years following its pathologic description, the cause of Alzheimer's disease (AD) remains unknown. To test the validity of present and future proposals related to the probable cause of AD, three postulates, or necessary conditions, are recommended by Jack de la Torre, MD, PhD, Adjunct Professor of Psychology at the University of Texas, Austin, in an article published in the Journal of Alzheimer's Disease.

20 Jun 2011

Scientists discover three susceptibility genes for development of progressive supranuclear palsy

An international research team, co-led by scientists at Mayo Clinic's campus in Florida, have discovered three potential susceptibility genes for development of progressive supranuclear palsy (PSP), a rare neurodegenerative disease that causes symptoms similar to those of Parkinson's disease but is resistant to Parkinson's medications.

20 Jun 2011

New insight into progressive supranuclear palsy

There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

20 Jun 2011

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

Biomedical engineers analyze and duplicate the neural mechanism of learning in rats

Scientists have developed a way to turn memories on and off-literally with the flip of a switch. Using an electronic system that duplicates the neural signals associated with memory, they managed to replicate the brain function in rats associated with long-term learned behavior, even when the rats had been drugged to forget.

17 Jun 2011

European scientists develop efficient methods for early diagnosis of Alzheimer's

PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer's disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples.

16 Jun 2011

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored.

16 Jun 2011

Olive oil may help prevent stroke in older people

A new study suggests that consuming olive oil may help prevent a stroke in older people. The research is published in the June 15, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

16 Jun 2011

Brain research funds crisis: Report

According to the European College of Neuropsychopharmacology there is a dramatic drop in private and public funding for research in brain diseases that has led to a “withdrawal of hope” for millions of sufferers and could delay the search for treatments and cures by 30 years.

16 Jun 2011

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

Dopamine replacement therapy, which is used to manage motor symptoms associated with Parkinson's disease, can, at times, adversely affect cognition.

15 Jun 2011

Servier, Cortex sign new option agreement for AMPAKINE technology

Cortex Pharmaceuticals, Inc. entered into a new agreement with Servier to sell its remaining rights to the jointly discovered high impact AMPAKINE compound, CX1632.

13 Jun 2011

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

13 Jun 2011

GE and Mayo Clinic receive $5.7 million NIH grant to study dedicated MRI brain scanner technology

Driving new technologies that will help expand the availability of MRI scanners beyond the hospital to smaller clinic settings, GE Global Research, the technology development arm for the General Electric Company, and Mayo Clinic, have received a five-year, $5.7 million grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the National Institute of Neurological Disorders and Stroke (NINDS), components of the National Institutes of Health.

10 Jun 2011

Older people who engage in moderate to intense exercise less likely to have silent strokes

Older people who regularly exercise at a moderate to intense level may be less likely to develop the small brain lesions, sometimes referred to as "silent strokes," that are the first sign of cerebrovascular disease, according to a new study published in the June 8, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011

Scientists find neuronal cells die in Alzheimer's disease

In what they are calling a new direction in the study of Alzheimer's disease, UC Santa Barbara scientists have made an important finding about what happens to brain cells that are destroyed in Alzheimer's disease and related dementias.

8 Jun 2011

McGill researcher develops speedier technique for predicting protein folding pathways

Protein folding has nothing to do with laundry. It is, in fact, one of the central questions in biochemistry. Protein folding is the continual and universal process whereby the long, coiled strings of amino acids that make up proteins in all living things fold into more complex three-dimensional structures.

8 Jun 2011

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.

8 Jun 2011

FDA approves Mylan's ANDA for Donepezil HCl Tablets to treat dementia linked with Alzheimer's

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease.

8 Jun 2011

Alzheimer's Disease News and Research

Further Reading

Wayne State team receives $330,000 NSF grant to develop 3-D neural probe for tinnitus

University of Texas professor recommends three postulates to find probable cause of AD

Scientists discover three susceptibility genes for development of progressive supranuclear palsy

New insight into progressive supranuclear palsy

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Biomedical engineers analyze and duplicate the neural mechanism of learning in rats

European scientists develop efficient methods for early diagnosis of Alzheimer's

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

Olive oil may help prevent stroke in older people

Brain research funds crisis: Report

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

Servier, Cortex sign new option agreement for AMPAKINE technology

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

GE and Mayo Clinic receive $5.7 million NIH grant to study dedicated MRI brain scanner technology

Older people who engage in moderate to intense exercise less likely to have silent strokes

Article reports on bright future and enormous need for stem cell therapeutics

Scientists find neuronal cells die in Alzheimer's disease

McGill researcher develops speedier technique for predicting protein folding pathways

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

FDA approves Mylan's ANDA for Donepezil HCl Tablets to treat dementia linked with Alzheimer's

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News